Literature DB >> 3330777

c-K-ras mutations in human carcinomas occur preferentially in codon 12.

L Yanez1, J Groffen, D M Valenzuela.   

Abstract

A study was carried out to determine the frequency and distribution of mutations in the c-K-ras gene in human carcinoma tissue. The study was done on a total of 51 lung, colon and breast carcinoma tumors using a panel of oligonucleotides coding for the wild type and all possible mutations in codons 12 and 61 of c-K-ras gene. Four of 16 colon carcinomas, two of 27 lung carcinomas and one of eight breast carcinomas were found to contain mutations in codon 12. No mutations were found at position 61. Of the six possible amino acid replacements in codon 12, all but one was represented in the seven mutations identified.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3330777

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Ras gene activation in malignant cells of human ovarian carcinoma peritoneal fluids.

Authors:  D N Dokianakis; M N Varras; M Papaefthimiou; J Apostolopoulou; H Simiakaki; E Diakomanolis; D A Spandidos
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

2.  Genetic mutations of p53 and k-ras in gastric carcinoma patients from Hunan, China.

Authors:  Han-Chun Chen; Hui-Juan Chen; Md Asaduzzaman Khan; Zhou-Zhou Rao; Xin-Xing Wan; Bo Tan; Dian-Zheng Zhang
Journal:  Tumour Biol       Date:  2010-11-16

3.  p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women.

Authors:  K Servomaa; A Kiuru; V M Kosma; P Hirvikoski; T Rytömaa
Journal:  Mol Pathol       Date:  2000-02

4.  Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?

Authors:  Photini F S Rice; Kevin G Ehrichs; Mykella S Jones; Hwudarw Chen; Chiu-Hsieh Hsu; Edward R Abril; Raymond B Nagle; David G Besselsen; Jennifer K Barton; Natalia A Ignatenko
Journal:  Cancer Prev Res (Phila)       Date:  2017-11-08

5.  Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis.

Authors:  Upal K Basu Roy; Rebecca S Henkhaus; Fotios Loupakis; Chiara Cremolini; Eugene W Gerner; Natalia A Ignatenko
Journal:  Int J Cancer       Date:  2013-02-12       Impact factor: 7.396

6.  A novel cell-based assay for the evaluation of anti-ras compounds.

Authors:  D C Jenkins; J N Stables; J Wilkinson; P Topley; L S Holmes; D J Linstead; E B Rapson
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

7.  c-Ki-ras mutations in colorectal adenocarcinomas from a country with a rapidly changing colorectal cancer incidence.

Authors:  W Y Tang; J Elnatan; Y S Lee; H S Goh; D R Smith
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

8.  MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice.

Authors:  Susanna Cogoi; Sonia Zorzet; Valentina Rapozzi; Imrich Géci; Erik B Pedersen; Luigi E Xodo
Journal:  Nucleic Acids Res       Date:  2013-03-06       Impact factor: 16.971

9.  Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction.

Authors:  James Butz; Eric Wickstrom; Jeremy Edwards
Journal:  BMC Biotechnol       Date:  2003-07-23       Impact factor: 2.563

10.  Structural polymorphism within a regulatory element of the human KRAS promoter: formation of G4-DNA recognized by nuclear proteins.

Authors:  Susanna Cogoi; Manikandan Paramasivam; Barbara Spolaore; Luigi E Xodo
Journal:  Nucleic Acids Res       Date:  2008-05-19       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.